{"id":"W4414011763","doi":"10.36401/jipo-25-11","title":"Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Journal of Immunotherapy and Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Loxo Oncology; Chugai Pharmaceutical; Foundation Medicine; Sierra Oncology; Servier; Ministry of Minority Affairs; European Society for Medical Oncology; Astellas Pharma; Eisai; Cancer Research UK; Seagen; Actuate Therapeutics; Pfizer; Incyte; NuCana; Moderna; Tarveda Therapeutics; Taiho Pharmaceutical; Christie Charity; MacroGenics; Sarcoma UK; Sanofi; GlaxoSmithKline; Amgen; Carrick Therapeutics; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biomarker; Oncology; Clinical trial; Medicine; Circulating tumor DNA; Internal medicine; Computational biology; Cancer; Biology; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006072323,0.0001310119,0.000587101,0.0001229876,0.0001140439,0.00005412244,0.0001577672,0.0001732158,0.00001681326],"category_scores_gemma":[0.01042283,0.0001069516,0.0002552637,0.0001185293,0.00004575455,0.00000621315,0.00005651699,0.0001377715,0.000001144444],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000342794,"about_ca_system_score_gemma":0.0005987188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007103649,"about_ca_topic_score_gemma":0.000009350601,"domain_scores_codex":[0.9976381,0.0004912122,0.001319642,0.0002238799,0.00008625189,0.0002408777],"domain_scores_gemma":[0.9961351,0.002620413,0.0006607939,0.0001509911,0.0003077131,0.0001250436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007283361,0.0002928597,0.002953244,0.000009781154,0.0003303175,0.00001091481,0.0001445208,0.00002243537,0.45085,0.00004173426,0.001783503,0.5362774],"study_design_scores_gemma":[0.03489448,0.03864172,0.02401327,0.0005950117,0.0004913427,0.000450369,0.0004286978,0.0005625681,0.1140283,0.004620809,0.7806802,0.0005933044],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719324,0.003801589,0.02197051,0.0006460994,0.0009391957,0.000559906,0.00001290914,0.000002827315,0.0001346221],"genre_scores_gemma":[0.9912888,0.001224576,0.004977617,0.001958469,0.0004048231,0.00003624344,0.000003863218,0.00001664758,0.00008897758],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7788966,"threshold_uncertainty_score":0.9979128,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1178469495001141,"score_gpt":0.4979265712615337,"score_spread":0.3800796217614197,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}